Abstract:Background We aimed to assess the value of induction chemotherapy with cisplatin and fluorouracil plus docetaxel (TPF) plus concurrent chemoradiotherapy (CCRT) versus CCRT alone in locoregionally advanced nasopharyngeal carcinoma (NPC). Methods We did an open-label phase 3 multicentre randomised controlled trial at ten institutions in China. Patients with stage III–IVB (except T3–4N0, UICC/AJCC 7th edition) NPC were randomly assigned to receive induction chemotherapy plus CCRT (investigational group) or CCRT alone (control group). Patients in both groups received cisplatin 100 mg/m2 every 3 weeks for three cycles, concurrently with intensity-modulated radiotherapy (IMRT). The investigational group received docetaxel (60 mg/m2 on day 1), cisplatin (60 mg/m2 on day 1), and fluorouracil (600 mg/m2 per day by continuous intravenous infusion on days 1–5) every 3 weeks for three cycles before CCRT. Our primary endpoint was failure-free survival (FFS), and the sample size was 476 patients (238 per treatment group). This trial is registered with ClinicalTrials.gov, NCT01245959. Findings 241 patients were assigned to the investigational group and 239 to the control group. After a median follow-up of 18.6 months (range 0.8–34 months), the estimated 2-year FFS was 82.2% in the investigational group and 75.5% in the control group (hazard ratio [HR] = 0.61, 95% confidence interval [CI] 0.39–0.97, p = 0.04). The estimated 2-year distant failure-free survival (D-FFS) was 91.3% in the investigational group and 81.7% in the control group (HR = 0.51, 95% CI 0.28–0.91, p = 0.02). No significant differences in overall survival and locoregional failure-free survival were observed between the two arms. The rates of grade 3–4 neutropenia, diarrhoea, and stomatitis during induction chemotherapy were 35.1%, 7.1%, and 6.3%, respectively. Interpretation The preliminary results suggested that compared with CCRT alone, induction chemotherapy with TPF could significantly improve FFS and D-FFS in locoregionally advanced NPC. Long-term follow-up is needed to establish an eventual efficacy of TPF induction chemotherapy. We aimed to assess the value of induction chemotherapy with cisplatin and fluorouracil plus docetaxel (TPF) plus concurrent chemoradiotherapy (CCRT) versus CCRT alone in locoregionally advanced nasopharyngeal carcinoma (NPC). We did an open-label phase 3 multicentre randomised controlled trial at ten institutions in China. Patients with stage III–IVB (except T3–4N0, UICC/AJCC 7th edition) NPC were randomly assigned to receive induction chemotherapy plus CCRT (investigational group) or CCRT alone (control group). Patients in both groups received cisplatin 100 mg/m2 every 3 weeks for three cycles, concurrently with intensity-modulated radiotherapy (IMRT). The investigational group received docetaxel (60 mg/m2 on day 1), cisplatin (60 mg/m2 on day 1), and fluorouracil (600 mg/m2 per day by continuous intravenous infusion on days 1–5) every 3 weeks for three cycles before CCRT. Our primary endpoint was failure-free survival (FFS), and the sample size was 476 patients (238 per treatment group). This trial is registered with ClinicalTrials.gov, NCT01245959. 241 patients were assigned to the investigational group and 239 to the control group. After a median follow-up of 18.6 months (range 0.8–34 months), the estimated 2-year FFS was 82.2% in the investigational group and 75.5% in the control group (hazard ratio [HR] = 0.61, 95% confidence interval [CI] 0.39–0.97, p = 0.04). The estimated 2-year distant failure-free survival (D-FFS) was 91.3% in the investigational group and 81.7% in the control group (HR = 0.51, 95% CI 0.28–0.91, p = 0.02). No significant differences in overall survival and locoregional failure-free survival were observed between the two arms. The rates of grade 3–4 neutropenia, diarrhoea, and stomatitis during induction chemotherapy were 35.1%, 7.1%, and 6.3%, respectively. The preliminary results suggested that compared with CCRT alone, induction chemotherapy with TPF could significantly improve FFS and D-FFS in locoregionally advanced NPC. Long-term follow-up is needed to establish an eventual efficacy of TPF induction chemotherapy.

Hypofractionated Radiotherapy compared with Conventionally Fractionated Radiotherapy to treat Initial Distant Metastases in Nasopharyngeal Carcinoma: A Multicenter, prospective, randomized, Phase II Trial

A Phase Iii Study of Late Course Accelerated Hyperfractionated Radiotherapy Versus Conventionally Fractionated Radiotherapy in Patients with Nasopharyngeal Carcinoma

Cisplatin and Fluorouracil Induction Chemotherapy With or Without Docetaxel in Locoregionally Advanced Nasopharyngeal Carcinoma.

Radiotherapy Alone Versus Concurrent Chemoradiotherapy in Intermediate Risk Nasopharyngeal Carcinoma: A Multicentre, Open-Label, Noninferiority, Randomised Phase III Trial.

WITHDRAWN: Interim Analysis of a Prospective Randomized Non-Inferiority Trial of Cisplatin and Fluorouracil Induction Chemotherapy with or Without Docetaxel in Nasopharyngeal Carcinoma

Phase I/II Trial Evaluating Carbon-Ion Radiotherapy for Salvage Treatment of Locally Recurrent Nasopharyngeal Carcinoma

Hyperfractionation compared with standard fractionation in intensity-modulated radiotherapy for patients with locally advanced recurrent nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trial

Neoadjuvant Chemotherapy Followed by Concurrent Chemoradiation for Locally Advanced Nasopharyngeal Carcinoma

The Effect of Accelerated Hyperfractionation Versus Conventional Radiotherapy in Nasopharyngeal Carcinoma

Neoadjuvant Chemotherapy Followed by Concurrent Chemoradiation for Locoregionally Advanced Nasopharyngeal Carcinoma Interim Results from 2 Prospective Phase 2 Clinical Trials

Survival Effects of Radiotherapy on Patients Newly Diagnosed with Distant Metastatic Nasopharyngeal Carcinoma in Non-High-Incidence Areas

Hyperfractionated radiotherapy: improvement of survival in locally advanced nasopharyngeal carcinoma

Reducing Target Volumes of Intensity Modulated Radiation Therapy After Induction Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma: Long-Term Results of a Prospective, Multicenter, Randomized Trial

Combined High-dose Radiation Therapy and Systemic Chemotherapy Improves Survival in Patients with Newly Diagnosed Metastatic Nasopharyngeal Cancer

Efficacy of Conventional Radiotherapy and Late Course Accelerated Hyperfractionationated Radiotherapy for Nasopharyngeal Carcinoma

Comparing Long-Term Survival and Late Toxicities of Different Sequential Chemotherapy Regimens with Intensity-Modulated Radiotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma

Long-term efficacy analysis of radiotherapy and local management of metastases in patients with newly diagnosed oligometastatic nasopharyngeal carcinoma: A prospective, single-arm, single-center clinical study

Reducing Target Volumes of Intensity-Modulated Radiotherapy Following Induction Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma: Long-Term Results of a Prospective, Multicenter, Randomized Trial

Intensity-modulated radiotherapy alone compared with intensity-modulated radiotherapy plus concurrent chemotherapy in intermediate-risk nasopharyngeal carcinoma

Low-dose fractionated radiotherapy combined with neoadjuvant chemotherapy for T3-4 nasopharyngeal carcinoma patients: Preliminary results of a phase II randomized controlled trial.

OP0010 Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: Preliminary results of a phase 3 multicentre randomised controlled trial